Dynacirc CR Related Published Studies
Well-designed clinical trials related to Dynacirc CR (Isradipine)
Phase II safety, tolerability, and dose selection study of isradipine as a
potential disease-modifying intervention in early Parkinson's disease
(STEADY-PD). [2013]
Effects of isradipine on cocaine-induced changes in cognitive performance in recently abstinent cocaine-dependent individuals. [2005.12]
Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects. [2005.06]
Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition. [2005.03]
Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals. [2005.01]
Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure. [2004.05.03]
Effects of isradipine on cocaine-induced subjective mood. [2004.04]
Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. [2003.07]
Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy. [2003.01]
[Comparison of nicardipine and isradipine in hypertension following coronary artery bypass graft] [2002.03]
Isradipine improves endothelium-dependent vasodilation in normotensive coronary artery disease patients with hypercholesterolemia. [2001.05]
A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension. [2001.05]
Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators. [2000.11]
Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. [2000.07.15]
Effects of enalapril and isradipine alone and in combination on blood pressure, renal function and echocardiographic parameters in mild hypertension. [2000.06.12]
Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected? [2000.04]
Long-term renal and cardiovascular effects of antihypertensive treatment regimens based upon isradipine, perindopril and thiazide. [2000]
Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on d-methamphetamine-induced reduction in hunger. [1999.10]
Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. [1999.10]
Short-term metabolic effects of isradipine and metoprolol in pre-eclampsia. [1999.08]
Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: a preliminary study. [1999.06]
An open trial comparing isradipine with hydralazine and methyl dopa in the treatment of patients with severe pre-eclampsia. [1999.05]
Isradipine in prediabetic hypertensive subjects. [1998.12]
Preeclampsia: haemostatic status and the short-term effects of methyldopa and isradipine therapy. [1998.06]
Effect of multiple doses of oral isradipine on atrioventricular conduction in patients with first-degree atrioventricular block. [1998.03]
Pro-haemorrhagic effects of calcium antagonists: a comparison of isradipine and atenolol on ex vivo platelet function in hypertensive subjects. [1997.12]
Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group. [1997.12]
Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension. [1997.11]
Antihypertensive and renal effects of isradipine in essential hypertension: focus on renin system activity. [1997.11]
Comparison of isradipine and enalapril effects on regional carotid circulation in patients with hypertension with unilateral internal carotid artery stenosis. [1997.11]
Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine. [1997.07]
Effect of isradipine on in-vivo platelet function. [1997.06.01]
Isradipine for the prevention of cyclosporine-induced hpertension in allogeneic bone marrow transplant recipients: a randomized, double-blind study. [1997.04.15]
Effect of calcium channel blockade on skin blood flow in diabetic hypertension: a comparison of isradipine and atenolol. [1997.03]
Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients. [1997.01]
Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. [1996.09.11]
Sustained blood pressure control with controlled-release isradipine (isradipine-CR). [1995.03]
Sustained blood pressure control with controlled-release isradipine. [1995.01]
Well-designed clinical trials possibly related to Dynacirc CR (Isradipine)
Pharmacotherapy review of chronic pediatric hypertension. [2011.10]
Glycemia in newborns of hypertensive mothers according to maternal treatment. [2004.10]
Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2. [2004]
[Effects of calcium antagonists on atherosclerosis progression and intima media thickness] [2000]
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. [1999.11.20]
The effect of four different antihypertensive medications on cardiovascular regulation in hypertensive sleep apneic patients--assessment by spectral analysis of heart rate and blood pressure variability. [1999.05]
Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. [1998.10]
Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. [1998.05]
Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing. [1998.03]
Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens. [1998.03]
New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. [1998]
Relationships between changes in left ventricular mass and in clinic and ambulatory blood pressure in response to antihypertensive therapy. [1997.12]
Salt and blood pressure responses to calcium antagonism in hypertensive patients. [1997.09]
Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. [1997.05]
Other research related to Dynacirc CR (Isradipine)
Pharmacokinetic properties of isradipine after single-dose and multiple-dose oral
administration in Chinese volunteers: a randomized, open-label, parallel-group
phase I study. [2013]
Physical properties and in vivo bioavailability in human volunteers of isradipine
using controlled release matrix tablet containing self-emulsifying solid
dispersion. [2013]
A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug. [2011.09]
L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. [2011.01]
Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. [2010.12.15]
Isradipine for treatment of acute hypertension in hospitalized children and adolescents. [2010.11]
Transdermal therapeutic system of isradipine: effect of hydrophilic and hydrophobic matrix on in vitro and ex vivo characteristics. [2010.07]
Isradipine antagonizes hypobaric hypoxia induced CA1 damage and memory impairment: Complementary roles of L-type calcium channel and NMDA receptors. [2009.05]
Brain MRI and neurological deficit measurements in focal stroke: rapid throughput validated with isradipine. [2008]
Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. [2006.07]
Calcium antagonist isradipine-induced calcium influx through nonselective cation channels in human gingival fibroblasts. [2006.03.27]
Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study. [2005.04]
A multicenter study using causal readings, self-recordings, and ambulatory blood pressure monitoring to assess isradipine effects. AMICUS Study Group. [1994.07]
Other possibly related research studies
A review of calcium channel antagonists in the treatment of pediatric hypertension. [2006]
Antihypertensive pharmacobezoar. [2006.04]
The importance of circadian rhythms on drug response in hypertension and coronary heart disease--from mice and man. [2006.09]
Dose- and administration time-dependent effects of nifedipine gits on ambulatory blood pressure in hypertensive subjects. [2007]
Chronotherapy With Nifedipine GITS in Hypertensive Patients: Improved Efficacy and Safety With Bedtime Dosing. [2008.08]
Time-dependent up-regulation of Ca(2+) channels in vas deferens of newborn rats fed with breast milk of mothers under treatment with nifedipine. [2008.12.03]
Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat. [2008.11]
Hypertensive emergency successfully treated with metoprolol: a case report. [2009.05]
Evaluation of the tablet core factors influencing the release kinetics and the loadability of push-pull osmotic systems. [2009.04]
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. [2009.03.15]
Membrane potential-dependent inactivation of voltage-gated ion channels in alpha-cells inhibits glucagon secretion from human islets. [2010.09]
A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. [2010]
Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials. [2011.11.09]
The role of calcium channel blockers and resveratrol in the prevention of paraquat-induced parkinsonism in Drosophila melanogaster: a locomotor analysis. [2011.06]
Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease:
evidence from observational studies and clinical trials. [2011]
Effects of prototypic calcium channel blockers in methadone-maintained humans
responding under a naloxone discrimination procedure. [2013]
|